Please login to the form below

Not currently logged in
Email:
Password:

Canbex hires former Lilly medical director

Alberto Lledó joins UK-based biotech

Dr Alberto Lledó has joined Canbex Therapeutics as chief medical officer.

Dr Lledó is currently a senior consultant neurologist at Clínica Creu Blanca in Barcelona, Spain, although has pharma experience that includes 16 years at Lilly from 1995 to 2011.

During his time at Lilly he served in several senior positions, including global senior medical adviser and CNS clinical research physician for Europe, and helped co-ordinate phase II clinical trials for the company's neurology pipeline.

As chief medical officer at Canbex Dr Lledó will lead preparations for proof of concept trials for the company's lead candidate VSN16R, an oral drug intended for the treatment of spasticity in people with multiple sclerosis.

"I am delighted to be joining Canbex at such an important time in the development of VSN16R," Dr Lledó said. "As a practicing neurologist and experienced drug developer, I am very pleased to be addressing a serious need among people with multiple sclerosis for improved treatment of their spasticity.”

4th March 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics